Physician profile
Helen C Wang
NPI 1730126921
$9,245.82
in general payments reported to CMS, 2019-2025
37 companies · $2,958 in 2025
The $2,958 reported for 2025 was more than what 75% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $149 · 2021: $662 · 2022: $1,354 · 2023: $1,373 · 2024: $2,027 · 2025: $2,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,290 · Education: $50.50 · Consulting Fee: $17.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,289.75 |
| Education | $50.50 |
| Consulting Fee | $17.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,125.45 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,712.84 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,183.36 | 2019-2025 | |
| Amgen INC. | $587.62 | 2021-2025 | Tezspire |
| Kaleo, INC. | $438.06 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $426.85 | 2022-2025 | Eohilia, Cuvitru, Takhzyro |
| Grifols USA, LLC | $322.64 | 2024-2025 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $308.67 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $296.75 | 2019-2025 | Dupixent |
| Csl Behring | $228.81 | 2024-2025 | Hizentra, Haegarda, Andembry |
| Ars Pharmaceuticals Operations, INC. | $221.00 | 2025 | Neffy |
| Blueprint Medicines Corporation | $164.03 | 2025 | Ayvakit |
| Pfizer INC. | $138.84 | 2019-2024 | |
| Octapharma USA, INC. | $138.69 | 2023-2025 | Cutaquig |
| Galderma Laboratories, L.P. | $138.63 | 2025 | Nemluvio |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.